- Prior ADT for non-metastatic disease with LHRH agonist or LHRH antagonist therapy in the neoadjuvant/adjuvant setting is permitted if total duration of therapy did not exceed 36 months, 6 months have elapsed since completion of therapy prior to consent, and serum testosterone > 50 ng/ml within 28 days prior to initiation of ADT.